AB-Biotics, chosen to participate in Prometheus acceleration program
<p>At the same time, the company has also signed an exclusive licensing agreement with ABBOT to distribute, promote and market one of their probiotics in Spain</p>
Biotechnology firm AB-Biotics, based at the University of Girona Science and Technology Park, has been chosen to participate in the Prometheus business acceleration program, an initiative of Reimagine Food.
The Prometheus program aims to create, train and advise potentially innovative and disruptive projects in the food and beverage sector, which will be presented at the Mobile World Congress 2015.
The AB-Biotics project sets out to formulate nutritional recommendations based on each consumer’s genetic profile. The test consists in isolating a genetic sample from the consumer’s saliva. The process doesn’t sequence the full genome; it does a genotyping to analyze the genetic variations that are different.
By participating in the Prometheus program, AB-Biotics will be eligible for a capitalizable loan to fund development of a business plan for a new subsidiary to be set up before the end of the year. They will also receive a capitalizable credit for mentoring services or strategic partners, among other items. In addition to the capital, the program will give the company access to a network of investors and a business coach, who will monitor the project over the four months of the program.
In addition to participating in the Prometheus program, AB-Biotics has also signed an agreement with ABBOT for the latter to distribute, promote and market one of the company’s probiotics, I3.1, which is a probiotic solution developed specifically to treat and improve irritable bowel syndrome.
Related news: